Elevated circulation postsynaptic density protein 95 as a potential biomarker for predicting the diagnosis and prognosis of acute cerebral infarction.

PURPOSE: Indices for the diagnosis of cerebral infarction (CI) and the prediction of prognosis are essential for timely and appropriate management. Plasma PSD95 levels, as a novel biomarker, have not yet been utilized for the diagnosis and prognosis of cerebral infarction. The purpose of this study was to investigate the correlation between plasma PSD95 levels and clinical characteristics as well as prognosis in patients with CI. METHODS: A total of 105 patients diagnosed with CI and 80 control group (CP) were enrolled. Plasma samples were collected and PSD95 levels were measured using enzyme-linked immunosorbent assay (ELISA). Neurological deficits in patients were evaluated using the National Institutes of Health Stroke Scale (NIHSS). Statistical analyses were conducted to assess the associations between plasma PSD95 levels, clinical parameters, and prognostic outcomes. RESULTS: Plasma PSD95 levels were significantly elevated in CI patients compared to CP (p < 0.01). Furthermore, within the CI group, PSD95 levels exhibited a negative correlation with activated partial thromboplastin time (APTT) (p < 0.05) and a significant positive correlation with NIHSS scores assessed 6 months post-onset (p < 0.05). CONCLUSION: Plasma PSD95 may serve as a potential diagnostic and prognostic biomarker for cerebral infarction.